The overall performance of PSMA-targeted PET/CT in detecting BC lesions was variable across the included papers, in per-patient- and per-lesion-based analyses in all the investigated clinical settings, without significant differences between the staging or restaging setting [20,21,22,23,24,25]. This evidence concerns the gene FOLH1 and breast cancer.